Gilda Tonziello

Gilda Tonziello

Auto-generated profile, based on publicly available information

Gilda Tonziello

Department of Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2009 in Hepatology
Verified
Journal Article
Open access
PDF file
ESEvangelista Sagnelli
Evangelista Sagnelli
Nicola CoppolaNicola Coppola
Nicola Coppola
MPMariantonietta Pisaturo
Mariantonietta Pisaturo
AMAddolorata Masiello
Addolorata Masiello
GTGilda Tonziello
Gilda Tonziello
PFPietro Filippini
Pietro Filippini
The impact of hepatitis B virus (HBV) superinfection in hepatitis C virus (HCV) chronic carriers was evaluated in a long-term follow-up study on 29 chronic anti-HCV carriers with acute hepatitis B (AVH-B) (Case group BC) and 29 anti-HCV negative patients with AVH-B (Control group B), pair-matched for age (±5 years), sex, and risk factors for the acquisition of HBV infection. Patients in Case group BC and those in Control group B showed similar initial HBV viral load and a similar trend of becoming negative for HBV-DNA. AVH-B showed a severe course more frequently in Case group BC than in Control group B (34.5% versus 6.9%, P < 0.05). Of the 28 patients in Case group BC alive at the end of the acute illness (one death from liver failure), 24 were followed up for 2-6 years, median 5 years: 22 patients became HBsAg-negative and two progressed to HBsAg-positive chronic hepatitis. HCV-RNA was undetectable in all patients during AVH-B; in the 24 patients with a long-term follow-up, HCV-RNA was detected in seven (29.2%) after 1 year, in 14 (58.3%) after 2 years, and in 18 (75%) after 3-6 years. The six patients who eradicated chronic HCV infection, compared with 18 showing reactivation of HCV replication, had higher values of aspartate aminotransferase and alanine aminotransferase and a higher prevalence of cases with severe AVH-B (83.3% versus 22.2%, P < 0.05). Conclusions: Although it can be life-threatening, HBV superinfection in HCV chronic carriers may lead to clearance of chronic HCV infection, especially in patients with severe AVH-B. (Hepatology 2009.)

3 July 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Nicola CoppolaNicola Coppola
Nicola Coppola
Nicoletta PotenzaNicoletta Potenza
Nicoletta Potenza
MPMariantonietta Pisaturo
Mariantonietta Pisaturo
NMNicola MOSCA
Nicola MOSCA
GTGilda Tonziello
Gilda Tonziello
ESEvangelista Sagnelli
Evangelista Sagnelli
To study in HBsAg chronic carriers the expression of liver hsa-miR-125a-5p and its correlation with liver HBV-DNA values and clinical presentation, 27 consecutive Caucasian, HBsAg/anti-HBe/HBV-DNA-positive patients who were naive to nucleos(t)ide analogues and interferon therapy and had no marker of HCV, HDV or HIV infection and no history of alcohol intake were enrolled. For each patient, liver HBV DNA and liver hsa-miR-125a-5p were quantified by real-time PCR in relation to β-globin DNA or RNU6B, respectively. Liver fibrosis and necroinflammation were graded by applying Ishak's scoring system. Liver hsa-miR-125a-5p was detected in all patients enrolled and a correlation between its concentration and liver HBV DNA was demonstrated (p103 IU/ml (p6 (p = 0.02) and those with fibrosis score >2 (p2 (p = 0.02) than in patients with a lower load. By multivariate logistic regression analysis, liver hsa-miR-125a-5p was identified as an independent predictor of disease progression: O.R. = 4.21, C.I. 95% = 1.08–16.43, p6; O.R. = 3.12, C.I. 95% = 1.17–8.27, p2. In conclusion, in HBsAg/anti-HBe-positive patients, the liver hsa-miR-125a-5p level correlated with liver and plasma HBV-DNA values and was associated to a more severe disease progression.

1 January 2012 in Digestive and Liver Disease
Verified
Journal Article
Closed access
Nicola CoppolaNicola Coppola
Nicola Coppola
MPMariantonietta Pisaturo
Mariantonietta Pisaturo
SGSalvatore Guastafierro
Salvatore Guastafierro
GTGilda Tonziello
Gilda Tonziello
ASAntonello Sica
Antonello Sica
ESEvangelista Sagnelli
Evangelista Sagnelli

23 August 2011 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
Nicola CoppolaNicola Coppola
Nicola Coppola
GTGilda Tonziello
Gilda Tonziello
MPMariantonietta Pisaturo
Mariantonietta Pisaturo
VMVincenzo Messina
Vincenzo Messina
SGSalvatore Guastafierro
Salvatore Guastafierro
ESEvangelista Sagnelli
Evangelista Sagnelli

18 December 2012 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
Nicola CoppolaNicola Coppola
Nicola Coppola
MPMariantonietta Pisaturo
Mariantonietta Pisaturo
GTGilda Tonziello
Gilda Tonziello
Caterina SagnelliCaterina Sagnelli
Caterina Sagnelli
ESEvangelista Sagnelli
Evangelista Sagnelli
IAItalo Francesco Angelillo
Italo Francesco Angelillo
Background: Two formulations of Pegylated interferon (Peg-IFN) are on the market for treatment of chronic hepatitis C virus (HCV) infection. The purpose of this meta-analysis was to assess the efficacy of Peg-IFN α-2a versus Peg-IFN α-2b in combination with ribavirin in anti-human immunodeficiency virus (HIV)-negative patients with genotype 1 chronic HCV infection. Methods: The following criteria were to be met for inclusion in the meta-analysis: (a) original data from randomized and non-randomized clinical trials; (b) study on the efficacy of conventional doses of Peg-IFN α-2a (180 μg/week) versus Peg-IFN α-2b (1.5 μg/kg of body weight/week), both in combination with ribavirin, in antiviral therapy-naïve HCV-genotype 1 subjects; (c) at least one of these primary outcomes: Rapid Virological Response (RVR); Early Complete Virological Response (EVR); End of Treatment Response (ETR); Sustained Virological Response (SVR); (d) odds ratio estimates of relative risk (RR) and associated 95% confidence intervals (CIs) or at least data enabling them to be computed; (e) English language; and (f) published as a full paper up to December 2011. Results: Seven published studies met the inclusion criteria, allowing a meta-analysis on 3,026 patients. Peg-IFN α-2a and Peg-IFN α-2b showed similar rate of RVR (RR = 1.05; 95% CI = 0.87-1.27, p = 0.62) and SVR (RR = 1.08; 95% CI = 0.99-1.18, p = 0.098). Peg-IFN α-2a more frequently than Peg-IFN α-2b achieved EVR (RR = 1.11; 95% CI = 1.02-1.21, p = 0.013) and ETR (RR = 1.22; 95% CI = 1.14-1.31, p < 0.0001). Conclusion: The standard schedules of Peg-IFN α-2a and Peg-IFN α-2b, both in combination with ribavirin, can be used indifferently for patients with chronic HCV genotype 1 who are anti- to eliminate HIV-negative and antiviral treatment-naïve.

16 September 2009 in Journal of Clinical Virology
Verified
Journal Article
Closed access
PDF file
Nicola CoppolaNicola Coppola
Nicola Coppola
RPRaffaella Pisapia
Raffaella Pisapia
GTGilda Tonziello
Gilda Tonziello
AMAddolorata Masiello
Addolorata Masiello
Salvatore MartiniSalvatore Martini
Salvatore Martini
ESEvangelista Sagnelli
Evangelista Sagnelli